Back to Stakeholders
Care Delivery & Psychedelic FacilitationPsychedelic Healthcare Implementation
Care Delivery & Psychedelic FacilitationPsychedelic Healthcare ImplementationPayer & Reimbursement Stakeholders

Veterans Health Administration (VHA) Pharmacy Benefits Management Services

U.S. Veterans Health Administration payer and formulary authority publishing criteria-for-use and national protocol documents for intranasal esketamine (Spravato).

Reimbursement & Market Access Snapshot

Insurance Payers & Reimbursement Specialists

Service Model

Public Payer / National Coverage Authority

Jurisdiction

National

Coverage

1 country

Last Verified

Apr 11, 2026

Focus Areas

Coverage Policy DesignFormulary & Access CriteriaReal-World Evidence for Access

Evidence Requirements

Clinical Efficacy EndpointsComparative EffectivenessLong-Term SafetyPatient-Reported Outcomes

Market Access Notes

VHA PBM documents include dedicated criteria-for-use and protocol guidance for intranasal esketamine in depression care pathways.

Verification

Verified

Psychedelic Focus

Explicit Psychedelic Focus

Engagement Status

Active

Primary Access Link

Linked Stakeholders

Institute for Clinical and Economic Review (ICER)

Source Evidence

VHA PBM Criteria for Use: Esketamine (Spravato)

https://www.va.gov/formularyadvisor/DOC_PDF/CFU_Esketamine_SPRAVATO_Criteria_rev_Oct_2025.pdf

VHA PBM National Protocol: Intranasal Esketamine for Depression

https://www.va.gov/formularyadvisor/DOC_PDF/CRE_Intranasal_Esketamine_for_Depression_National_Protocol_Rev_Oct_2025_.pdf

Quick Facts

Website
Visit